{
  "ticker": "BOT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973118",
  "id": "02973118",
  "pages": 11,
  "price_sensitive": true,
  "date": "20250728",
  "time": "0902",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m66lt7hhth9j.pdf",
  "summary": "Here's the concise extraction of material information relevant for trading or capital markets decisions:  \n\n### **Key Highlights (Quarterly Report & Appendix 4C)**  \n- **Revenue & Commercial Progress**:  \n  - Sofdra\u2122 net revenue grew **324% QoQ** ($4.3M vs. $0.7M in Q3).  \n  - Prescriptions shipped: **13,647 (Q4) vs. 3,222 (Q3)**.  \n  - Unique prescribers increased **115%** to 2,316.  \n  - Gross-to-net (GTN) settled at **23%**, targeting 30\u201340% long-term.  \n\n- **Capital Raising & Financing**:  \n  - **$40M institutional placement** completed (April 2025).  \n  - **$30M debt facility secured** (Kreos Capital), with **$30.7M drawn** and **$15.3M undrawn** (milestone-dependent).  \n\n- **Cash Position**:  \n  - **$64.9M cash on hand** (30 June 2025); **estimated 2.8 quarters of funding** based on current burn.  \n  - Operating cash outflow: **$28.4M** (driven by $11.2M inventory spend, now complete for 1H FY26).  \n\n- **Operational Expansion**:  \n  - Sales force expanded from **27 to 33 reps**; **17 additional hires planned for Q2 FY26**.  \n\n- **Milestone**: FDA-approved Sofdra\u2122 remains the **only treatment** for primary axillary hyperhidrosis in the US.  \n\n*No material omissions or unsupported forward-looking statements included.*",
  "usage": {
    "prompt_tokens": 6483,
    "completion_tokens": 357,
    "total_tokens": 6840,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T23:23:19.657232"
}